Why this fund manager is 'very happy' to own this ASX 200 share

The ASX 200 stock has come under some selling pressure in 2023, but this fundie sees better days ahead.

| More on:
A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

S&P/ASX 200 Index share CSL Ltd (ASX: CSL) is historically a long-term outperformer. But the stock has struggled in 2023.

Shares in the biotechnology company are currently trading for $266.80 apiece, down 5.3% since the opening bell of 3 January. That compares to a 3% gain posted by the ASX 200.

Here's why the ASX 200 share has come under pressure. And why this fund manager is "very happy" to own the biotech company.

What's happening with the ASX 200 share?

As you can see in the chart above, the CSL share price really hit some turbulence on 14 June.

That came after the ASX 200 share announced a downgrade of its FY 2023 profit guidance. This was driven by higher than initially forecast foreign currency headwinds.

At the time, CSL revised its forecast for its full-year net profits after tax and amortisation (NPATA) to the range of US$2.9 billion to US$3 billion in constant currency.

That revision saw the ASX 200 share close the day down 6.9%.

CSL reported its audited results on 15 August. And NPATA came in right near the bottom end of that forecast, at US$2.86 billion.

Other highlights of the FY 2023 results included a 31% increase in revenue in constant currency to US$13.31 billion. And the full-year dividend increased 6% to US$2.36 per share.

Management also reaffirmed its FY 2024 guidance. They expect NPATA of in the range of US$2.9 billion to US$3 billion in constant currency. And FY 2024 revenue growth of 9% to 11%.

Which brings us to Patrick Hodgens, managing director Firetrail Investments.

CSL counts amongst the biggest holdings at Firetrail Investments' high conviction fund.

And Hodgens wasn't put off by the ASX 200 share's results.

According to The Australian Financial Review, Firetrail believes this is a case of CEO Paul McKenzie "looking to reset".

According to Hodgens:

We're very happy to be owning CSL over the medium term and, in fact, we bought quite a bit more on the back of that perceived weakness by the market. We think CSL has some really good earnings upside if you look out two to three years.

CSL share price snapshot

As mentioned above, the CSL share price has underperformed in 2023 and over the past 12 months.

The ASX 200 share has outperformed longer-term, up 27% in five years.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

This stock has made millions for investors over just a few months.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

Has the Pro Medicus share price risen too high too quickly?

Pro Medicus shares have rocketed 173% since this time last year.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Mergers & Acquisitions

Own Sigma shares? Here's the latest on the Chemist Warehouse merger

One year ago today, the two companies announced plans to merge. We could now be just a few months away…

Read more »

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

'Huge opportunity' ahead for this ASX 200 healthcare stock

The ASX 200 healthcare stock is facing a large untapped market for its lead products.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Should I buy CSL shares today?

With CSL’s valuation improving, is the ASX 200 biotech stock one to buy today?

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Healthcare Shares

Why is this ASX healthcare stock crashing 26% today?

Let's find out what is causing investors to hit the sell button on Monday.

Read more »

Medical or healthcare workers grasp hands in the universal expression of teamwork
Healthcare Shares

What's the diagnosis for ASX healthcare shares in 2025?

Do we have a healthy future in store?

Read more »